GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SQZ Biotechnologies Co (OTCPK:SQZB) » Definitions » Return-on-Tangible-Equity

SQZ Biotechnologies Co (SQZ Biotechnologies Co) Return-on-Tangible-Equity : -715.85% (As of Sep. 2023)


View and export this data going back to 2020. Start your Free Trial

What is SQZ Biotechnologies Co Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. SQZ Biotechnologies Co's annualized net income for the quarter that ended in Sep. 2023 was $-94.56 Mil. SQZ Biotechnologies Co's average shareholder tangible equity for the quarter that ended in Sep. 2023 was $13.21 Mil. Therefore, SQZ Biotechnologies Co's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2023 was -715.85%.

The historical rank and industry rank for SQZ Biotechnologies Co's Return-on-Tangible-Equity or its related term are showing as below:

SQZB' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -188.22   Med: -87.75   Max: -54.74
Current: -186.28

During the past 5 years, SQZ Biotechnologies Co's highest Return-on-Tangible-Equity was -54.74%. The lowest was -188.22%. And the median was -87.75%.

SQZB's Return-on-Tangible-Equity is ranked worse than
84.54% of 1307 companies
in the Biotechnology industry
Industry Median: -48.28 vs SQZB: -186.28

SQZ Biotechnologies Co Return-on-Tangible-Equity Historical Data

The historical data trend for SQZ Biotechnologies Co's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SQZ Biotechnologies Co Return-on-Tangible-Equity Chart

SQZ Biotechnologies Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22
Return-on-Tangible-Equity
- - -188.22 -54.74 -87.75

SQZ Biotechnologies Co Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -115.55 -86.20 -145.42 -207.38 -715.85

Competitive Comparison of SQZ Biotechnologies Co's Return-on-Tangible-Equity

For the Biotechnology subindustry, SQZ Biotechnologies Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SQZ Biotechnologies Co's Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SQZ Biotechnologies Co's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where SQZ Biotechnologies Co's Return-on-Tangible-Equity falls into.



SQZ Biotechnologies Co Return-on-Tangible-Equity Calculation

SQZ Biotechnologies Co's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2022 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=-79.464/( (123.976+57.148 )/ 2 )
=-79.464/90.562
=-87.75 %

SQZ Biotechnologies Co's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Sep. 2023 )  (Q: Jun. 2023 )(Q: Sep. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Sep. 2023 )  (Q: Jun. 2023 )(Q: Sep. 2023 )
=-94.556/( (24.537+1.881)/ 2 )
=-94.556/13.209
=-715.85 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


SQZ Biotechnologies Co  (OTCPK:SQZB) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


SQZ Biotechnologies Co Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of SQZ Biotechnologies Co's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


SQZ Biotechnologies Co (SQZ Biotechnologies Co) Business Description

Traded in Other Exchanges
N/A
Address
200 Arsenal Yards Boulevard, Suite 210, Watertown, MA, USA, 02472
SQZ Biotechnologies Co is a clinical-stage biotechnology company developing transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. Using its proprietary technology, SQZ has the ability to deliver multiple materials into many patient cell types to engineer what it believes to be an unprecedented range of potential therapeutics for a range of diseases. The company has the potential to create well-tolerated cell therapies that can provide therapeutic benefit for patients and potentially improve the patient experience over existing cell therapy approaches, with accelerated production timelines under 24 hours and the elimination of preconditioning and lengthy hospital stays.
Executives
Richard Capasso officer: See Remarks C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Marshelle Smith Warren officer: Chief Medical Officer C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Klavs F. Jensen director C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Amy W Schulman director, 10 percent owner PFIZER INC. ATTN: CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Bernard Coulie director C/O PLIANT THERAPEUTICS, INC., 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Vink Patrick V.j.j. director ETZELSTRASSE 20, 8707 UETIKON AM SEE V8 V8
Temasek Holdings (private) Ltd 10 percent owner 60B ORCHARD ROAD #06-18 TOWER 2, THE ATRIUM@ORCHARD, SINGAPORE U0 238891
Invus Public Equities, L.p. 10 percent owner C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022
American International Group, Inc. 10 percent owner 1271 AVE OF THE AMERICAS, FL 37, NEW YORK NY 10020-1304
Polaris Entrepreneurs' Fund Vii, L.p. 10 percent owner ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210
S.a. Westend 10 percent owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Artal Group S.a. 10 percent owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Arny Schulman, As Trustee The Armon R. Sharei Irrevocable Gst Trust Of 2016 U/d/t Dated December 29, 2016 10 percent owner C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Marc Elia director C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Armon Sharei director, officer: President and CEO C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472

SQZ Biotechnologies Co (SQZ Biotechnologies Co) Headlines

From GuruFocus

SQZ Biotechnologies to Present at Jefferies Healthcare Conference

By Business Wire Business Wire 06-01-2022